The development and progression of MASLD is majorly driven by alterations in lipid profiles induced by SREBP activation or repression and alteration of different signaling pathways, such as PI3K-PKB-AKT-mTORC1 [54]. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.